Diabetologie und Stoffwechsel 2022; 17(S 01): S23
DOI: 10.1055/s-0042-1746273
Abstracts | DDG
02. Poster
Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
Dominik Dahl
1
Gemeinschaftspraxis für Inner Medizin und Diabetologie, -, Hamburg, Germany
,
Yukiko Onishi
2
The Institute of Medical Science, Asahi Life Foundation, Tokyo, Japan
,
Paul Norwood
3
Valley Endocrine and Research, -, Fresno, United States
,
Ruth Huh
4
Eli Lilly and Company, -, Indianapolis, United States
,
Hiren Patel
4
Eli Lilly and Company, -, Indianapolis, United States
,
Angel Rodriguez
4
Eli Lilly and Company, -, Indianapolis, United States
› Author Affiliations
